Search
ozanimod (Zeposia)
Indications:
- multiple sclerosis
- ulcerative colitis [1] (FDA-approved)
Dosage:
- titration to maintenance dose of 0.92 mg orally once daily
Capsules: 0.23 mg, 0.46 mg, 0.92 mg
Adverse effects:
- most common (> 4%)
- upper respiratory infection
- hepatic transaminase elevation
- orthostatic hypotension
- hypertension
- urinary tract infection
- back pain
Mechanism of action:
- sphingosine 1-phosphate receptor modulator
General
neurologic agent
receptor antagonist
Database Correlations
PUBCHEM cid=52938427
References
- Walsh N
Ozanimod a Winner in Ulcerative Colitis -
S1P receptor modulator effective for both induction and maintenance.
MedPage Today December 10, 2020
https://www.medpagetoday.com/meetingcoverage/aibd/90136
- Sandborn W, et al
Ozanimod efficacy, safety, and histology in patients with moderate-to-severe
ulcerative colitis during induction in the phase 3 True North study.
Advances in Inflammatory Bowel Diseases (AIBD) 2020; Poster 025.
- Danese S, et al
Ozanimod efficacy, safety, and histology in patients with moderate-to-severe
ulcerative colitis during maintenance in the phase 3 True North study.
Advances in Inflammatory Bowel Diseases (AIBD) 2020; Poster 030.
- Hamza Z
Ozanimod Wins FDA Approval in Ulcerative Colitis
- S1P receptor modulator indicated for moderate to severe disease.
MedPage Today May 28, 2021
https://www.medpagetoday.com/gastroenterology/inflammatoryboweldisease/92844
- HIGHLIGHTS OF PRESCRIBING INFORMATION
ZEPOSIA (ozanimod) capsules, for oral use
https://packageinserts.bms.com/pi/pi_zeposia.pdf